The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $64.5 Milhão dollars as of 16 August 2018. Advisors Capit owns over 521,607 units of Glaukos stock worth over $8,736,934 and over the last 7 years Advisors sold GKOS stock worth over $55,724,902.
Advisors has made over 7 trades of the Glaukos stock since 2018, according to the Form 4 filled with the SEC. Most recently Advisors sold 521,607 units of GKOS stock worth $5,189,990 on 16 August 2018.
The largest trade Advisors's ever made was selling 1,368,796 units of Glaukos stock on 7 August 2018 worth over $13,646,896. On average, Advisors trades about 584,381 units every 26 days since 2018. As of 16 August 2018 Advisors still owns at least 69,617 units of Glaukos stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Advisors's mailing address filed with the SEC is 601 LEXINGTON AVENUE601 LEXINGTON AVENUE, 54TH FLOOR54TH FLOOR, NEW YORKNEW YORK, NYNY, 1002210022.
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman, eJonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: